Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Codexis, Inc.NASDAQ: CDXS

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables falls 30.7% from a year ago

Net receivables stood at $8.03M at the end of Q1 FY2026, down 30.7% from a year earlier and down 25.2% from the prior quarter. Over 3 fiscal years it compounded at -36.0% a year.

Context

  • Net receivables amounted to 6.2% of total assets at the end of Q1 FY2026, down 2.8 pp from a year earlier.
  • Net receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -30.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.03M-25.2% QoQ
Last fiscal yearDec 2025
$10.73M-43.2% YoY
Year agoMar 2025
$11.59M-30.7% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.7%——
1 year-43.2%——
3-year CAGR-36.0%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
10.73M USD
Year-over-year change
-43.2%
4-year CAGR
-26.9%

Net Receivables vs competitors

How CDXS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -30.7% is the 7th highest of 10, against a peer median of +39.5%.
  • Net receivables amounts to 6.2% of total assets for CDXS, versus a peer median of 4.1%.
CDXS Competitors
Net Receivables for CDXS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OABIOmniAb, Inc.Mar 2026$12.64M USD+95.1%-37.5%4.3%
IVVDInvivyd, Inc.Mar 2026$12.21M USD+39.5%+238.3%5.1%
CDXSCodexis, Inc.Mar 2026$8.03M USD-30.7%-36.0%6.2%
IPHAInnate Pharma S.A.Dec 2025€7.61M EUR+363.2%+34.3%12.1%
SGMOSangamo Therapeutics, Inc.Mar 2026$6.36M USD+38.1%+33.0%10.6%
CCCCC4 Therapeutics, Inc.Mar 2026$2.88M USD-64.1%+17.7%0.9%
RANIRani Therapeutics Holdings, Inc.Mar 2026$2.11M USD+252.2%—4.1%
TARAProtara Therapeutics, Inc.Mar 2026$1.52M USD+312.2%+37.3%0.8%
IMDXInsight Molecular Diagnostics Inc.Mar 2026$157K USD-95.6%-17.5%0.4%
ARMPArmata Pharmaceuticals, Inc.Mar 2026$47K USD-80.3%-37.5%0.1%
Peer median (excluding CDXS) —+39.5%+25.3%4.1%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents116.8M113.98M65.12M19.26M50.79M
Short-term Investments00054.19M27.42M
Net Receivables37.65M40.87M19.93M18.88M10.73M
Inventory1.16M2.03M2.69M1.8M1.82M
Other Current Assets579K521K5.74M4.63M6.06M
Total Current Assets161.89M162.89M93.47M98.77M96.82M
Property, Plant & Equipment (Net)65.46M61.88M28.62M42.9M43.53M
Goodwill3.24M3.24M2.46M2.46M2.46M
Intangible Assets00000
Long-term Investments14M20.51M9.7M2.8M2.5M
Tax Assets00000
Other Non-current Assets1.8M1.87M2.31M2.08M2.5M
Total Non-current Assets84.5M87.5M43.1M50.24M50.98M
Total Assets246.38M250.39M136.56M149.01M147.8M
Account Payables3M3.25M5.95M2.84M1.55M
Short-term Debt00000
Tax Payables00000
Deferred Revenue2.59M13.73M10.12M350K7.01M
Other Current Liabilities11.12M11.45M11.25M11.41M11.04M
Total Current Liabilities33.37M49.07M35.83M23.65M25.32M
Long-term Debt00028.91M40.11M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)3.75M16.88M640K100K360K
Other Non-current Liabilities1.31M1.37M1.23M1.27M1.33M
Total Non-current Liabilities48.62M56.53M14.12M58.44M71.95M
Total Liabilities81.99M105.6M49.95M82.08M97.27M
Common Stock6K6K7K8K9K
Retained Earnings(387.7M)(421.29M)(497.53M)(562.81M)(606.78M)
Accumulated OCI00052K8K
Other Stockholders Equity00000
Minority Interest00000
Total Equity164.39M144.8M86.62M66.93M50.53M
Total Debt47.65M43.64M16.02M59.9M73.21M
Net Debt(69.14M)(70.35M)(49.09M)40.63M22.42M

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.